Qi Yan, Huang Yalan, Pang Lijuan, Gu Wenyi, Wang Ning, Hu Jianming, Cui Xiaobin, Zhang Jun, Zhao Jin, Liu Chunxia, Zhang Wenjie, Zou Hong, Li Feng
Department of Pathology and Key Laboratories for Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, Australia.
Clin Exp Pharmacol Physiol. 2017 Apr;44(4):441-454. doi: 10.1111/1440-1681.12726.
MicroRNAs (miRNAs) in cancer development have attracted much attention in recent years. miR-29 is known to critically affect cancer progression by functioning as a tumor suppressor. However, it may also act as an oncogene under certain situations. The prognostic value of the miR-29 family in cancer progression is still under debate and reported results are inconsistent. Therefore, we reported here a meta-analysis and systematic review to analyze the prognostic role of the miR-29 family in cancer. We screened 20 published studies and calculated pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS) or disease-free survival/recurrence-free survival (DFS/RFS). Our results showed that a low or absent expression of miR-29 family was significantly associated with poor OS (HR, 1.57; 95%CI, 1.18-2.08), and inferior to 5-year DFS/RFS (HR, 1.89; 95%CI, 1.47-2.44). Analysis of individual miR-29 subtypes indicated that the low expression of miR-29a/b/c subtypes correlated with poor 5-year OS (miR-29a: HR, 1.99; 95%CI, 1.41-2.80; miR-29b: HR, 1.60; 95%CI, 1.18-2.17; miR-29c: HR, 1.69; 95%CI, 1.00-2.86), as well as poor 5-year DFS/RFS (miR-29b: HR, 1.70; 95%CI, 1.27-2.27). Ethnicity analysis demonstrated Asian patients with low expression of miR-29 were significantly correlated with poor OS (HR, 1.61; 95%CI, 1.16-2.23) and 5-year DFS/RFS (HR, 2.03; 95%CI, 1.50-2.74). Taken together, our analysis indicates that the low expression of miR-29 is associated with aggressiveness and poor prognosis of malignant neoplasms. More importantly, miR-29 might serve as a key biomarker for predicting the recurrence and progression of human cancers.
近年来，微小RNA（miRNA）在癌症发展中的作用备受关注。已知miR-29作为一种肿瘤抑制因子，对癌症进展具有关键影响。然而，在某些情况下它也可能充当癌基因。miR-29家族在癌症进展中的预后价值仍存在争议，且报道结果不一致。因此，我们在此报告一项荟萃分析和系统评价，以分析miR-29家族在癌症中的预后作用。我们筛选了20项已发表的研究，并计算了总生存期（OS）或无病生存期/无复发生存期（DFS/RFS）的合并风险比（HR）及相应的95%置信区间（CI）。我们的结果显示，miR-29家族低表达或缺失与较差的OS显著相关（HR，1.57；95%CI，1.18 - 2.08），且5年DFS/RFS较差（HR，1.89；95%CI，1.47 - 2.44）。对单个miR-29亚型的分析表明，miR-29a/b/c亚型低表达与较差的5年OS相关（miR-29a：HR，1.99；95%CI，1.41 - 2.80；miR-29b：HR，1.60；95%CI，1.18 - 2.17；miR-29c：HR，1.69；95%CI，1.00 - 2.86），以及较差的5年DFS/RFS（miR-29b：HR，1.70；95%CI，1.27 - 2.27）。种族分析表明，miR-29低表达的亚洲患者与较差的OS（HR：）显著相关，1.61；95%CI，1.16 - 2.23）和5年DFS/RFS（HR，2.03；95%CI，1.50 - 2.74）。综上所述，我们的分析表明miR-29低表达与恶性肿瘤的侵袭性及不良预后相关。更重要的是，miR-29可能作为预测人类癌症复发和进展的关键生物标志物。
